Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
10.3350/cmh.2014.20.3.274
- Author:
Jeong Han KIM
1
;
Hee Won MOON
;
Soon Young KO
;
Won Hyeok CHOE
;
So Young KWON
Author Information
1. Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. 93haan@hanmail.net
- Publication Type:Original Article
- Keywords:
Hepatitis B, Chronic;
Hepatitis B surface antigen;
Lamivudine;
Adefovir;
Resistance
- MeSH:
Adenine/*therapeutic use;
Adult;
Antiviral Agents/*therapeutic use;
Area Under Curve;
DNA, Viral/blood;
Drug Resistance, Viral;
Female;
Hepatitis B Surface Antigens/*blood;
Hepatitis B virus/genetics;
Hepatitis B, Chronic/*drug therapy/virology;
Humans;
Lamivudine/*therapeutic use;
Male;
Middle Aged;
Organophosphates/*therapeutic use;
ROC Curve;
Treatment Outcome
- From:Clinical and Molecular Hepatology
2014;20(3):274-282
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determine the treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement during rescue therapy for lamivudine (LMV)-resistant CHB patients have not been evaluated to date. Therefore, this study investigated the correlation between HBsAg level and treatment response in LMV-resistant CHB patients treated with adefovir (ADV) add-on therapy. METHODS: LMV-resistant CHB patients treated with LMV-ADV combination therapy for over 2 years were included. HBsAg levels were measured at 6 month intervals until 1 year, and annually thereafter. Treatment response was assessed by determining the virological response (VR, undetectable HBV DNA levels) during treatment. RESULTS: Fifty patients were included, of which 40 showed a VR. HBsAg levels were not different significantly at baseline (4.0 vs. 3.6 Log10 IU/mL, P=0.072). However, the HBsAg level decreased after 6 months of treatment in patients with a VR and became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, P=0.002; 3.8 vs. 3.2 at 1 year, P=0.004; 3.9 vs. 3.2 at 2 years, P=0.008; 3.7 vs. 3.1 at 3 years, P =0.020). CONCLUSIONS: The HBsAg level at 6 months after treatment can help predict treatment response.
